Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice - A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra

被引:445
作者
Joosten, LAB [1 ]
Helsen, MMA [1 ]
vandeLoo, FAJ [1 ]
vandenBerg, WB [1 ]
机构
[1] UNIV NIJMEGEN HOSP,DEPT RHEUMATOL,6500 HB NIJMEGEN,NETHERLANDS
来源
ARTHRITIS AND RHEUMATISM | 1996年 / 39卷 / 05期
关键词
D O I
10.1002/art.1780390513
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To examine the role of tumor necrosis factor alpha (TNF alpha), interleukin-1 alpha (IL-1 alpha), and IL-1 beta in collagen-induced arthritis (CIA), immediately after onset and during the phase of established arthritis. Methods. Male DBA/1 mice with collagen-induced arthritis were treated with antibodies against murine TNF alpha and IL-1 alpha/beta at different time points of the disease. IL-1 receptor antagonist (IL-1Ra) was administered using Alzet osmotic minipumps. The effect of anticytokine treatment was monitored by visual scoring, Histology and cytokine reverse transcription polymerase chain reaction (RT-PCR) analyses were performed at the end of the treatment period. Results. Anti-TNF alpha treatment showed efficacy shortly after onset of the disease, but had little effect on fully established CIA. Histologic analysis after early treatment revealed that anti-TNF alpha significantly reduced joint pathology, as determined by infiltration of inflammatory cells and cartilage damage. Anti-IL-1 alpha/beta treatment ameliorated both early and full-blown CIA. This clear suppression of established arthritis was confirmed by administration of high doses of IL-1Ra. Dose-response experiments showed that a continuous supply of 1 mg/day was needed for optimal suppression, Histologic analysis showed markedly reduced cartilage destruction both in the knee and the ankle joints, Autoradiography demonstrated full recovery of chondrocyte synthetic function of articular cartilage. In addition, we found that the IL-1 beta isoform plays a dominant role in established CIA. Profound suppression of CIA was observed with anti-IL-1 beta, although elimination of both IL-1 alpha and IL-1 beta still gave better protection, Analysis of messenger RNA with RT-PCR revealed that IL-1 beta was highly upregulated in synovium and cartilage at late stages of CIA, whereas anti-IL-1 beta treatment markedly reduced IL-1 beta message in the synovium. Conclusion. The present study identified different TNF alpha/IL-1 dependencies in various stages of CIA and revealed that blocking of TNF alpha does not necessarily eliminate IL-1. Continuous, high doses of IL-1Ra are needed to block CIA.
引用
收藏
页码:797 / 809
页数:13
相关论文
共 59 条
  • [1] BIOLOGICAL PROPERTIES OF RECOMBINANT HUMAN MONOCYTE-DERIVED INTERLEUKIN-1 RECEPTOR ANTAGONIST
    AREND, WP
    WELGUS, HG
    THOMPSON, RC
    EISENBERG, SP
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1990, 85 (05) : 1694 - 1697
  • [2] INHIBITION OF THE PRODUCTION AND EFFECTS OF INTERLEUKIN-1 AND TUMOR-NECROSIS-FACTOR-ALPHA IN RHEUMATOID-ARTHRITIS
    AREND, WP
    DAYER, JM
    [J]. ARTHRITIS AND RHEUMATISM, 1995, 38 (02): : 151 - 160
  • [3] INTERLEUKIN-1 RECEPTOR ANTAGONIST
    AREND, WP
    [J]. ADVANCES IN IMMUNOLOGY, VOL 54, 1993, 54 : 167 - 227
  • [4] BRENNAN FM, 1989, LANCET, V2, P244
  • [5] Caccese R G, 1992, Mediators Inflamm, V1, P273, DOI 10.1155/S0962935192000425
  • [6] RESTRICTED CYTOKINE EXPRESSION IN RHEUMATOID-ARTHRITIS
    CHEN, E
    KEYSTONE, EC
    FISH, EN
    [J]. ARTHRITIS AND RHEUMATISM, 1993, 36 (07): : 901 - 910
  • [7] CHENSUE SW, 1993, J IMMUNOL, V151, P3654
  • [8] DYSREGULATION OF THE IN-VIVO PRODUCTION OF INTERLEUKIN-1 RECEPTOR ANTAGONIST IN PATIENTS WITH RHEUMATOID-ARTHRITIS - PATHOGENETIC IMPLICATIONS
    CHIKANZA, IC
    ROUXLOMBARD, P
    DAYER, JM
    PANAYI, GS
    [J]. ARTHRITIS AND RHEUMATISM, 1995, 38 (05): : 642 - 648
  • [9] SINGLE-STEP METHOD OF RNA ISOLATION BY ACID GUANIDINIUM THIOCYANATE PHENOL CHLOROFORM EXTRACTION
    CHOMCZYNSKI, P
    SACCHI, N
    [J]. ANALYTICAL BIOCHEMISTRY, 1987, 162 (01) : 156 - 159
  • [10] COOPER WO, 1992, CLIN EXP IMMUNOL, V89, P244